Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: A developing diagnostic and therapeutic relationship

BJU International

Volumn 97, Issue 5, 2006, Pages 916-922

  Lawrentschuk, Nathan ^a,b,c   Davis, Ian D ^a,b   Bolton, Damien M ^a   Scott, Andrew M ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Diagnostic imaging; Monoclonal antibodies; Positron emission tomography; Radio immunodetection; Radionuclide imaging; Renal neoplasms

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 FLUORO 2 DEOXY DEXTRO GLUCOSE 6 PHOSPHATE F 18; ACETIC ACID C 11; BROMINE 75; CARBACHOL; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; FLUOROMETHYLCHOLINE F 18; FLUOROTHYMIDINE F 18; GALIXIMAB; IODINE 124; METHIONINE C 11; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY G250 I 124; MONOCLONAL ANTIBODY G250 I 131; MONOCLONAL ANTIBODY G250 TC 99M; MONOCLONAL ANTIBODY G250 ZR 89; OXYGEN 15; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 86; ZIRCONIUM 89;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; DRUG UPTAKE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY SCINTISCANNING; LYMPH NODE METASTASIS; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOIMMUNOSCINTIGRAPHY; RADIOIMMUNOTHERAPY; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TISSUE DISTRIBUTION; TUMOR VOLUME;

ACETATES; CARCINOMA, RENAL CELL; CHOLINE; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 33645744465     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06125.x     Document Type: Short Survey

References (41)

1. Lindner V Lang H Jacqmin D Pathology and genetics in renal cell cancer In Jacqmin D ed EAU Update Series: Renal Cell Cancer Oxford, UK Elsevier 2003 197 208
2. Novick AC Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma Semin Oncol 1995 22 29 33
3. Brush JP Positron emission tomography in urological malignancy Curr Opin Urol 2001 11 175 9
4. Hara T 18F-fluorocholine: a new oncologic PET tracer J Nucl Med 2001 42 1815 7
5. Townsend DW Beyer T A combined PET/CT scanner: the path to true image fusion Br J Radiol 2002 75 Spec no S24 30
6. Ramdave S Thomas GW Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma J Urol 2001 166 825 30
7. Kang DE White RL Zuger JH Sasser HC Teigland CM Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma J Urol 2004 171 1806 9
8. Majhail NS Urbain JL Albani JM et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma J Clin Oncol 2003 21 3995 4000
9. Jadvar H Kherbache HM Pinski JK Conti PS Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma Clin Nephrol 2003 60 395 400
10. Chang CH Shiau YC Shen YY Kao A Lin CC Lee CC Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography - a preliminary report Urol Int 2003 71 306 9
11. Miyakita H Tokunaga M Onda H et al. Significance of 18F- fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer Int J Urol 2002 9 15 8
12. Brouwers AH Dorr U Lang O et al. 131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study Nucl Med Commun 2002 23 229 36
13. Safaei A Figlin R Hoh CK et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer Clin Nephrol 2002 57 56 62
14. Montravers F Grahek D Kerrou K et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera J Nucl Med 2000 41 78 84
15. Goldberg MA Mayo-Smith WW Papanicolaou N Fischman AJ Lee MJ FDG PET characterization of renal masses: preliminary experience Clin Radiol 1997 52 510 5
16. Hoh CK Seltzer MA Franklin J deKernion JB Phelps ME Belldegrun A Positron emission tomography in urological oncology J Urol 1998 159 347 56
17. Bachor R Kotzerke J Gottfried HW Brandle E Reske SN Hautmann R[ Positron emission tomography in diagnosis of renal cell carcinoma] Urologe A 1996 35 146 50
18. Bachor R Kocher F Gropengiesser F Reske SN Hautmann RE [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results] Urologe A 1995 34 138 42
19. Kocher F Grimmel S Hautmann R et al. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm J Nucl Med 1994 35 Suppl. 223P 224P
20. Wahl RL Harney J Hutchins G Grossman HB Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F) -fluoro- d -glucose: pilot animal and human studies J Urol 1991 146 1470 4
21. Lawrentschuk N Gani J Rowden R Esler S Bolton DM Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review BJU Int 2005 96 291 5
22. Heidenreich A Ravery V Preoperative imaging in renal cell cancer World J Urol 2004 22 307 15
23. Peterson JJ Kransdorf MJ O'Connor MI Diagnosis of occult bone metastases: positron emission tomography Clin Orthop Rel Res 2003 415 Suppl S120 8
24. Ballinger JR Imaging hypoxia in tumors Semin Nucl Med 2001 31 321 9
25. Hockel M Vaupel P Biological consequences of tumor hypoxia Semin Oncol 2001 28 Suppl. 2 36 41
26. Vaupel P Mayer A Hockel M Tumor hypoxia and malignant progression Methods Enzymol 2004 381 335 54
27. 18F-fluoromisonidazole Int J Radiat Oncol Biol Phys 1992 22 199 212
28. Nunn A Linder K Strauss HW Nitroimidazoles and imaging hypoxia Eur J Nucl Med 1995 22 265 80
29. Lawrentschuk N Poon AM Foo SS et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography BJU Int 2005 96 540 6
30. Shreve P Chiao PC Humes HD Schwaiger M Gross MD Carbon-11-acetate PET imaging in renal disease J Nucl Med 1995 36 1595 601
31. de Certaines JD Larsen VA Podo F Carpinelli G Briot O Henriksen O In vivo 31P MRS of experimental tumours NMR Biomed 1993 6 345 65
32. Mathews D Oz OK Positron emission tomography in prostate and renal cell carcinoma Curr Opin Urol 2002 12 381 5
33. Vansteenkiste JF Stroobants SG Positron emission tomography in the management of non-small cell lung cancer Hematol Oncol Clin North Am 2004 18 269 88
34. Schwartz JL Tamura Y Jordan R Grierson JR Krohn KA Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs J Nucl Med 2003 44 2027 32
35. Zuckier LS DeNardo GL Trials and tribulations: oncological antibody imaging comes to the fore Semin Nucl Med 1997 27 10 29
36. Brouwers A Verel I Van Eerd J et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats Cancer Biother Radiopharm 2004 19 155 63
37. Oosterwijk E Brouwers A Boerman OC et al. Monoclonal antibody therapy of kidney cancer Cancer Treat Res 2003 116 199 212
38. Lam JS Pantuck AJ Belldegrun AS Figlin RA G250: a carbonic anhydrase IX monoclonal antibody Curr Oncol Rep 2005 7 109 15
39. Steffens MG Oosterwijk E Kranenborg MH et al. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations J Nucl Med 1999 40 829 36
40. Czuczman MS Thall A Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma J Clin Oncol 2005 23 4390 8
41. Divgi CR O'Donoghue JA Welt S et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer J Nucl Med 2004 45 1412 21